GIVE YOUR PATIENTS FASTER ADMINISTRATION WITH RITUXAN HYCELA—PREFERRED BY MORE PATIENTS BECAUSE OF LESS TIME IN CLINIC 1,†
  • Nearly 8 in 10 patients preferred RITUXAN HYCELA administration vs RITUXAN® (rituximab) because of less time in clinic
  • RITUXAN HYCELA is a combination of RITUXAN and hyaluronidase human, a substance that increases the body’s absorption of co-administered drugs when given subcutaneously
  • All patients must complete at least one full dose of RITUXAN before starting treatment with RITUXAN HYCELA
  • RITUXAN HYCELA is given as a subcutaneous injection in the abdomen and patients should be monitored for at least 15 minutes post-administration

*Refers to actual RITUXAN HYCELA injection time of 5 or 7 minutes and does not account for all aspects of treatment. Actual clinic time may vary.
The PrefMab Trial, studied in previously untreated DLBCL and follicular lymphoma, demonstrated that 77% of patients preferred subcutaneous administration of RITUXAN HYCELA vs rituximab IV after Cycle 8 (n=620) as it required less time in clinic.

Review the clinical development program
Learn about RITUXAN HYCELA dosing & administration
Download resources for you and your patients